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S160 Oral PresentationsIf PB CD34 was\ 10/mL on day 5, plerixafor (0.24 mg/kg sc) was
administered in the evening 5 and apheresis was commenced the
next day. If daily yield was \ 0.5  106CD34/kg, plerixafor was
added. In Dec 2009, the algorithm was changed to Plerixafor-2.
The dosing of G-CSF and plerixafor remained the same, however
the thresholds changed to if day 4 PB CD34 \ 10 for single or
\20/mL for multiple transplants, plerixafor was added. If day 1 yield
was\1.5  106 CD34/kg, or any subsequent daily yield was\ 0.5,
plerixafor was added.
In the 3 time periods, Jan-Dec 2008, there were 327 mobiliza-
tion attempts in 286 patients, Feb-Nov 2009, 228 mobilization at-
tempts in 224 pts, and Dec 2009-June 2010, 101 attempts in 100
pts. Costs of the mobilization and collection included drugs costs
(cyclophosphamide, G-CSF, GM-CSF and plerixafor), apheresis
and cryopreservation. Supportive care costs of transfusions, anti-
biotics, hospitalizations, nursing costs and patients personal costs
were not included. The details of the results are outlined in the
table. Plerixafor-2 shows a statistical improvement PBSC collec-
tions, increased number of patients reaching minimum and opti-
mal goals, less days of apheresis and total days of mobilization/
collection.
In conclusion, although the earlier identification of ineffective
PBSC mobilization and initiation of plerixafor (Plerixafor-2) in-
creases the costs of PBSC mobilization, more patients are able to
achieve the minimum and optimal goals of CD34 collection, failure
rates, number of days of apheresis and total days of mobilization/
collection are lower. It is unclear if upfront mobilization with plerix-
afor 1 G-CSF would result in further benefit.
Table 1. Results of Mobilization and Collection
Baseline2008 Plerixafor-1 Plerixafor-2 P valuePatients 286 224 100Mobilization
Attempts/
Remobilizations327/ 41 (14%) 228/ 4 (2%) 101/ 1 (1%)CD34 collected
- x106/kgMedian 5.34 6.04 7.72 <0.001Range 0-25.8 0.1-28.2 1.48-29.3Mean 5.66 6.86 8.16Collections
>4 x106/kg (%)223 (68%) 185 (81%) 93 (92%) <0.001Collections
>2x106/kg(%)261 (80%) 212 (93%) 99 (97%) <0.001Mobilization Failures 66 (20%) 16 (7%) 1 (1%) <0.001Days of ApheresisMedian 2 3 2 0.002Range 0-11 1-12 1-9Mean 2.6 3.1 2.5Total Days of
Mobilization/
CollectionMedian 8 8 6Range 4-28 4-25 4-22Mean 9 8.9 7.2 <0.001Total Cost
per patientMedian $12 500 $12 500 $21 000 <0.001Minimum $3000 $5000 $5500Maximum $146 750 $93 500 $89 750Mean $17 300 $21 686 $20 695Plerixafor Use 29 # (9%) 94 (41%) 60 (59%)Days- Median 5 3 2 <0.001Range 1-10 1-8 1-9Mean 5 3.3 2.6Bone Marrow
Harvest*3 0 0#All remobilizations were on the compassionate use protocol. Costs
were based on current pricing of plerixafor;
*Cost of bone marrow harvest not inclusded in costs per patient.GVH/GVL
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A NOVEL ROLE FOR LYMPHOCYTE EXPRESSION OF THE CYCLIN-DEPEN-
DENT KINASE 5 (Cdk5) IN THE GENERATIONOF ALLOGENEIC T CELL RE-
SPONSES AFTER BMT
Askew, D.1, Pareek, T.1, Eid, S.1, Keller, M.1, Guardia-Wolff, R.1,
Pierce, E.1, Huang, A.Y.1,2, Letterio, J.1,2, Cooke, K.R.1,2 1Case Western
Reserve University School of Medicine, Cleveland, OH; 2Rainbow Babies
and Children’s Hospital, Cleveland, OH
Cdk5 is a ubiquitously expressed serine/threonine kinase. Cdk5
and its obligate partners p35 and p39 are required for neuronal de-
velopment and migration. Activation of the Cdk5/p35 complex is as-
sociated with inflammatory disorders, but the contribution of Cdk5
activity to T cell activation has not been explored. Using a mouse
BMT model (B6/ B6D2F1), we reveal a critical role for Cdk5 in
the induction of GVHD.TCR stimulation leads to a rapid induction
of Cdk5/p35 expression and function, and Cdk5 activity is increased
in the spleen and intestine of mice with GVHD. To study the role of
Cdk5 in T cells, we generated chimeric mice (Cdk52/2C) by recon-
stituting irradiated B6mice with hematopoietic progenitors from the
liver and spleen of E16.5 Cdk51/1 and Cdk52/2 littermate embryos;
germ line deletion of the Cdk5 gene is embryonically lethal. BMT
using B6 Cdk52/2C donors and lethally irradiated F1 hosts resulted
in a dramatic reduction in mortality (25% vs. 92%) and systemic
GVHD (p \ 0.01) compared to mice receiving B6 Cdk51/1C
BMT. Similar findings were seen in GVHD across an isolated
MHC-II mismatch, but were less apparent in a MHC class I dispa-
rate model, suggesting that Cdk5 was functioning primarily through
CD41 T cells. Mixing studies in the B6/F1 model showed that
CDk5 expression in purified T cells (compared to BM) was predom-
inantly responsible for reduced GVHD, and while a survival advan-
tage was maintained in GVL experiments, Cdk52/2C BMT was
associated with more leukemic deaths. Functional characterization
of Cdk52/2C T cells showed modest reductions in T cell prolifera-
tion to host antigens, but no differences in cytokine production or
CTL activity. However, donor splenic T cell numbers were mark-
edly reduced on days 7, 10 and 14 after Cdk52/2C BMT (p \
0.01), findings that were associated with reductions in day 7 serum
IFNg levels. Further studies showed that Cdk5 phosphorylates the
actin modulator Coronin 1a on threonine 418. Activated Cdk52/2
T cells lack this post-translational modification, exhibit defective
TCR-induced actin polarization and reduced migration towards
CCL-19.Co-migration studies using flow cytometry and intravitalmi-
croscopy revealed significant reductions in homing of Cdk52/2C
T cells (CD4 . CD8) to spleen and lymph nodes, but once entered,
the migration speed of Cdk52/2 T cells was not altered. Collectively,
our data define a novel role for Cdk5 in lymphocyte biology and allo-
geneic T cell responses after BMT.27
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Background: In 2005, the NIH Consensus Project proposed the
cGVHD severity score to standardize clinician evaluation and stag-
ing of cGVHD.This analysis was conducted to validateNIH scoring
variables as adequate determinants of disease severity.
Methods: 189 adults were enrolled on the prospective NCI cross-
sectional cGVHDnatural history study between 2004-2010.Median
age was 46 yrs (18–70), median time from transplant was 35 mos
Oral Presentations S161(3.5–255) and median prior therapies was 4 (0–9). 88% were classi-
fied as classic and 12% as overlap. Median follow-up of surviving
pts was 30.3 mos (1-70). NIH scores for key organs and global sever-
ity were compared to sub-specialist evaluations (SSE) and 10 contin-
uous outcome measures [Lee Symptom Scale; SF-36 (physical/
mental); FACT-BMT; HAP score (MAS/AAS), 2 min walk test,
grip strength, and joint ROM]. NIH scores were compared to cate-
gorical outcomes: intensity of immunosuppression scale (IIS), ther-
apeutic intent at enrollment (TI) and clinician 7-point global
assessment of change (CGA).
Table 1. NIH Scores
NIH Global Score N (%)1 5 mild 2 (1)
2 5 moderate 62 (33)
3 5 severe 125 (66)
NIH Organ Score N (%) NIH Organ Score N (%)
Skin Liver
0 5 none 42 (22) 0 5 none 91 (48)
1 5 mild 30 (16) 1 5 mild 64 (34)
2 5 moderate 46 (24) 2 5 moderate 34 (18)
3 5 severe 71 (38) 3 5 severe 0
Mouth Lungs
0 5 none 59 (31) 0 5 none 45 (24)
1 5 mild 104 (55) 1 5 mild 79 (42)
2 5 moderate 23 (12) 2 5 moderate 42 (22)
3 5 severe 3 (1.5) 3 5 severe 23 (12)
Eyes Joints and Fascia
0 5 none 33 (17) 0 5 none 75 (40)
1 5 mild 66 (35) 1 5 mild 40 (21)
2 5 moderate 69 (36) 2 5 moderate 55 (29)
3 5 severe 21 (11) 3 5 severe 19 (10)
GI Tract Genital (female
only n5 90)
0 5 none 107 (57) 0 5 none 46 (51)
1 5 mild 62 (33) 1 5 mild 13 (14)
2 5 moderate 14 (7) 2 5 moderate 13 (14)
3 5 severe 6 (3) 3 5 severe 18 (9)NIH - National Institutes of Health, N - number, GI - gastrointestinal.
Results: 125/189 had a severeNIH global score; mean number of in-
volved organs was 4.8 (1-8) with a mean average NIH score of 1.09
(0.14-2.14). NIH scores for skin, mouth, eyes and female genital cor-
responded to SSE scores and standard measures: skin % BSA, oral
Schubert score, and Schirmer’s test, each with two-sided P values of
\0.0001. Joints/fascia, skin, lungandNIHglobal scores showedhigh-
est number of significant associations with outcomes. Joints/fascia and
skin scores, but not lung,were significantly associatedwith IIS,TI, and
CGA.AverageNIH scores adjusted for gender, were highly associated
with SSE, IIS, TI and CGA. In univariate analyses, lung scores of 3 vs.
\3had3yearprojectedsurvivalof 28%(95%CI12-83%)vs. 87%(CI:
80-92%) respectively. In multivariate analysis, adjusting for demo-
graphic and clinical parameters [including known predictors of
cGVHD mortality: Karnofsky score (KS), platelet count, and biliru-
bin], the final model contained KS .80 vs.\80 (HR 5 0.43; p 5
0.025) and NIH lung score of 3 vs. 0-2 (HR5 8.9; p\0.0001).
Conclusions: High association of NIH scores with SSE suggests
they are appropriate for clinical and research assessment, perhaps
substituting for complex sub-specialist evaluations. In moderate to
severely affected pts high NIH lung score is the most powerful inde-
pendent predictor of poor survival. These results indicate the NIH
severity score is reliable for assessing cGVHD.28
EARLY CYTOMEGALOVIRUS REPLICATION AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION IS ASSOCIATED WITH A DRAMATICALLY
REDUCED RELAPSE RISK IN ACUTE MYELOID LEUKEMIA PATIENTS:
EVIDENCE FOR A PUTATIVE VIRUS-VERSUS-LEUKEMIA EFFECT
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Cytomegalovirus (CMV) reactivation after allogeneic stem cell
transplantation (alloSCT) is commonly regarded as an adverse and po-
tentially hazardous event. In-vitro and animal data point to anti-tu-
moral effects of CMV infection, which may also play a role after
alloSCT. This prompted us to investigate the influence of early
CMV replication in 266 consecutive adult (median age [years]: 47,
19–73) acute myeloid leukemia (AML) patients (pts), who received
transplants from 10/10 high-resolution HLA-matched unrelated (n
5 148) or related (n 5 118) donors. Sixty-three % of pts (n 5 167)
were at risk for CMV replication based on either patient or donor pre-
transplant serostatus. After a median of 45 (25–108) days, first CMV
replication as detected by pp65 antigenemia assay occurred in 77
pts, of whom 4 pts had a seronegative patient and donor CMV seros-
tatus. Taking competing risks into account, the cumulative incidence
of hematologic relapse (CIR) at 10 years after alloSCT was 42 % (95
%confidence limit [95%CL]: 35–51) in pts without compared to 9%
(95 % CL: 4–19) in pts with pp65 antigenemia (p\ 0.0001). In mul-
tivariate analysis using time-dependent covariate functions for the de-
velopment of grades II-IV acute graft-versus-host disease (GvHD),
chronic GvHD, and pp65 antigenemia, CMV replicative status was
confirmed as a strong independent predictor of relapse (hazard ratio
[HR]: 0.19, 95 % CL: 0.08–0.44, p\ 0.0001) together with chronic
GvHD (HR: 0.23, 95%CL: 0.13-0.42, p\0.0001), and disease stage
(HR: 1.56, 95% CL: 1.22-2.06, p\0.0005). The antileukemic effect
was detectable across all prognostic genetic AML subsets and was par-
ticular pronounced in pts with intermediate/unfavourable karyotypes
(10-year CIR: 48 % without vs. 10 % with pp65 antigenemia, p\
0.0001). It was completely conserved in a 100-day landmark analysis
of relapse-free surviving pts (n 5 238) in multivariate analysis. This
translated into superior overall survival (OS) and event-free survival
(EFS) estimates at 10 years for pts with early CMV replication (OS:
63 % with vs. 36 % without pp65 antigenemia, p\ 0.0005; EFS: 63
% with vs. 38 % without pp65 antigenemia, p\ 0.0005). In conclu-
sion, this is the first report which demonstrates a strong and indepen-
dent effect of early CMV replication on the leukemic relapse risk in
a homogeneous population of adult AMLpts. This effect deserves fur-
ther andmore comprehensive studies to elucidate its clinical relevance
and the underlying antileukemic mechanisms.29
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Relapse is a major cause of mortality after allogeneic hematopoi-
etic cell transplant (allo-HCT). Graft-versus-tumor effect is medi-
ated primarily by T-cells. CTLA-4 is a critical inhibitor of T-cell
proliferation. Single nucleotide polymorphisms (SNPs) in CTLA-
4 have been associated with various autoimmune disorders and solid
organ allograft rejection. We hypothesized that genetic variation in
donor CTLA-4 would impact relapse-free survival (RFS) and overall
survival (OS) of recipients after allo-HCT independent of chronic
graft-versus-host disease (cGVHD) status.
Adult patients undergoing allo-HCT (cord transplant excluded) at
a single center (1999-2008), with a minimum survival of 120 days,
and with the availability of pre-transplant recipient and donor
germline DNA samples were included (n 5 164). Ten tagSNPs of
the CTLA-4 gene (rs231775, rs231779, rs11571315, rs231777,
rs3087243, rs16840252, rs231725, rs4553808, rs10197010,
rs11571316) were identified using previously published criteria. All
SNPs analyzed passed quality control [test ofHardy-Weinberg equi-
librium (HWE) P . 0.001, MAF . 0.10, SNP call rate . 0.95, and
pair-wise r2 value less than 0.8].
Table 1 outlines the patient characteristics. In univariate analyses,
the donor SNP rs4553808 A/A genotype was associated with
